Azoulay, L, Yin, H, Renoux, C (2011) The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Research and Treatment, 129: 541–8.
Bargiota, SI, Bonotis, KS, Messinis, IE, et al (2013) The effects of antipsychotics on prolactin levels and women's menstruation. Schizophrenia Research and Treatment, (http://dx.doi.org/10.1155/2013/502697).
Barnes, TRE (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 25: 567–620.
Ben-Jonathan, N, Hugo, ER, Brandebourg, TD, et al (2006) Focus on prolactin as a metabolic hormone. Trends in Endocrinology and Metabolism, 17: 110–6.
Bostwick, JR, Guthrie, SK, Ellingrod, VL (2009) Antipsychotic-induced hyperprolactinemia. Pharmacotherapy, 29: 64–73.
Buckley, PF, Correll, CU (2008) Strategies for dosing and switching antipsychotics for optimal clinical management. Journal of Clinical Psychiatry, 69: 4–17.
Bushe, C, Shaw, M (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. Journal of Psychopharmacology, 21: 768–73.
Chen, CK, Huang, YS, Ree, SC, et al (2010) Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 34: 1495–9.
Citrome, L (2008) Current guidelines and their recommendations for prolactin monitoring in psychosis. Journal of Psychopharmacology, 22: 90–7.
Correll, CU, Detraux, J, De Lepeleire, J, et al (2015) Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry, 14: 119–36.
Crews, MP, Howes, OD (2012) Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Human Psychopharmacology, 27: 15–23.
De Berardis, D, Fornaro, M, Serroni, N, et al (2014) Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 8: 30–7.
De Hert, M, Correll, CU, Bobes, J, et al (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry, 10: 52–77.
De Hert, M, Peuskens, J, Sabbe, T, et al (2016) Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatrica Scandinavica, 133: 5–22.
Ezzat, S, Asa, SL, Couldwell, WT, et al (2004) The prevalence of pituitary adenomas: a systematic review. Cancer, 101: 613–9.
Freeman, ME, Kanyicska, B, Lerant, A, et al (2000) Prolactin: structure, function, and regulation of secretion. Physiological Reviews, 80: 1523–631.
Froes Brandao, D, Strasser-Weippl, K, Goss, PE (2016) Prolactin and breast cancer: the need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients. A review. Cancer, 122: 184–8.
Harvey, PW, Everett, DJ, Springall, CJ (2008) Adverse effects of prolactin in rodents and humans: breast and prostate cancer. Journal of Psychopharmacology, 22: 20–7.
Holt, RI, Peveler, RC (2011) Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clinical Endocrinology, 74: 141–7.
Inder, WJ, Castle, D (2011) Antipsychotic-induced hyperprolactinaemia. Australian & New Zealand Journal of Psychiatry, 45: 830–7.
Ishioka, M, Yasui-Furukori, N, Sugawara, N, et al (2015) Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers. Neuropsychiatric Disease and Treatment, 11: 477–84.
Klibanski, A, Biller, BM, Rosenthal, DI et al (1999) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. Journal of Clinical Endocrinology & Metabolism, 67: 124–30.
Landgraf, R, Landraf-Leurs, MM, Weissmann, A, et al (1977) Prolactin: a diabetogenic hormone. Diabetologia, 13: 99–104.
Lee, BH, Han, CS, Kim, KH (2005) Treatment in risperidone-induced amenorrhoea. International Journal of Psychiatry in Clinical Practice, 9: 29–34.
Li, X, Tang, Y, Wang, C (2013) Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One, 8: e7017.
Lodhi, RJ, Masand, S, Malik, A (2016) Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study. Schizophrenia Research, 170: 245–51.
Madhusoodanan, S, Parida, S, Jimenez, C (2010) Hyperprolactinemia associated with psychotropics: a review. Human Psychopharmacology, 25: 281–97.
Melmed, S, Casanueva, FF, Hoffman, AR, et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 96: 273–88.
Milano, W, D'Acunto, CW, De Rosa, M, et al (2011) Recent clinical aspects of hyperprolactinemia induced by antipsychotics. Reviews on Recent Clinical Trials, 6: 52–63.
National Institute for Health and Care Excellence (2014a) Psychosis and Schizophrenia in Adults: Prevention and Management
National Institute for Health and Care Excellence (2014b) Bipolar Disorder: Assessment and Management
O'Keane, V (2008) Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. Journal of Psychopharmacology, 22: 70–5.
Peuskens, J, Pani, L, Detraux, J, et al (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs, 28: 421–53.
Peveler, RC, Branford, D, Citrome, L, et al (2008) Antipsychotics and hyperprolactinaemia: clinical recommendations. Journal of Psychopharmacology, 22: 98–103.
Rahman, T, Clevenger, CV, Kaklamani, V, et al (2014) Antipsychotic treatment in breast cancer patients. American Journal of Psychiatry, 171: 616–21.
Ranjbar, F, Sadeghi-Bazargani, H, Niari Khams, P, et al (2015) Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia. Neuropsychiatric Disease and Treatment, 11: 549–55.
Riecher-Rössler, A, Rybakowski, JK, Pflueger, MO (2013) Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychological Medicine, 43: 2571–82.
Serri, O, Chik, CL, Ur, E, et al (2003) Diagnosis and management of hyperprolactinemia. Canadian Medical Association Journal, 169: 575–81.
Shimatsu, A, Hattori, N (2012) Macroprolactinemia: diagnostic, clinical, and pathogenic significance. Clinical and Developmental Immunology, .
Takeuchi, H, Remington, G (2013) A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology, 228: 175–85.
Torre, DL, Falorni, A (2007) Pharmacological causes of hyperprolactinemia. Therapeutics and Clinical Risk Management, 3: 929–51.
Tsuboi, T, Bies, RR, Suzuki, T, et al (2013) Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 45: 178–82.
Wang, AT, Mullan, RJ, Lane, MA, et al (2012) Treatment of hyperprolactinemia: a systematic review and meta-analysis. Systematic Reviews, 1: 33.
Wennbo, H, Gebre-Medhin, M, Gritli-Linde, A, et al (1997) Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. Journal of Clinical Investigation, 100: 2744–51.
Wong-Anuchit, C (2016) Clinical management of antipsychotic-induced hyperprolactinemia. Perspectives in Psychiatric Care, 52: 145–52.
Wu, H, Deng, L, Zhao, L, et al (2013) Osteoporosis associated with antipsychotic treatment in schizophrenia. International Journal of Endocrinology, .